The IPO Buzz: Phaos Technology Cayman (Holdings) (POAS) Prices IPO at $4 – Low End

Phaos Technology Cayman (Holdings) Ltd. (POAS) of Singapore priced its micro-cap IPO at $4.00 – the low end of its $4.00-to-$5.00 range – and sold 2.7 million shares – the number in the prospectus – to raise $10.8 million on Wednesday night, Nov. 12, 2025. In addition selling shareholders sold 900,090 shares at $4.00 each and their proceeds totaled $3.6 million. The company will not receive any proceeds from the sale of the selling shareholders’ stock. Phaos Technology’s IPO raised a total of $14.4 million.

At pricing, Phaos Technology had a market cap of $53.8 million.

Phaos Technology Cayman (Holdings) Ltd. (POAS) slid at the opening to $3.70 – down 30 cents from its IPO price -in its debut today – Thursday, Nov. 13, 2025 – on the NYSE – American Exchange (NYSE-AmEx). But the stock eventually found its footing. By early afternoon, Phaos Technology’s stock was trading at $4.22 – up 22 cents from its IPO price – on the NYSE-AmEx.

Network 1 Financial Securities served as the sole book-runner.

Phaos Technology Cayman (Holdings) Ltd. is a Singapore-based investment company whose main subsidiary makes advanced microscopes that can see up to 137 nanometers. In comparison, traditional microscopes see only up to 250 nm. The company also provides software

 “We distribute our microscopy products with software solutions through an extensive network of distributors, primarily in Singapore, and expanding across regions such as Southeast Asia and South Asia,” Phaos Technology said in the prospectus.

“Our microscopy solutions accommodate a diverse range of applications enabling us to serve a wide range of customer needs and capitalize on emerging growth opportunities in the region. Our diverse customer base primarily includes industries with usage in fields such as manufacturing, research & development, biomedical, semiconductors, Printed Circuit Board (“PCB”), electronics, precision engineering, injection molding, research, healthcare, QA/QC and diagnostics. Our business strategic focus involves strengthening our market position in Singapore and progressively expanding into the Southeast Asian region.”

The company is not profitable: It reported a net loss of $1.73 million on revenue of $1.38 million for the year that ended April 30, 2024, according to financial statements in the prospectus.

(For more information about these companies, please check the IPO Calendar  and the individual IPO Profiles found on the IPOScoop.com  website.) 

Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board. 

To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message. 

Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.

Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and the rating is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy